Sprycel (dasatinib) - Important Safety Information from Bristol-Myers Squibb as approved by the Irish Medicines Board
15 August 2011
Important Safety Information communication from Bristol-Myers Squibb on the potential risk of pre-capillary pulmonary arterial hypertension (PAH) associated with Sprycel (dasatinib).
Important Safety Information - Sprycel